Results 161 to 170 of about 23,218 (270)

Proprotein convertase subtilisin kexin type 9 (PCSK9) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres [PDF]

, 2017
Monika Kohli, Kinjal Prahaladbhai Patel, Zofia MacMahon, Radha Ramachandran, Martin Crook, Tim Reynolds, Anthony S. Wierzbicki   +6 more
openalex   +1 more source

Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]

J Transl Med
Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Pistritto C, Tiralongo M, Di Stefano C, Pennisi G, De Francesco EM, Malaguarnera R, Di Pino A, Piro S, Scicali R.   +13 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9 (PCSK9) [PDF]

Science-Business eXchange, 2012
openaire   +1 more source

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]

Sci Rep
Dermiki-Gkana F, Gravel CA, Kontogiorgis C, Douros A.   +3 more
europepmc   +1 more source

The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Active Site and Cleavage Sequence Differentially Regulate Protein Secretion from Proteolysis [PDF]

, 2014
John S. Chorba, Kevan M. Shokat
openalex   +1 more source

Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study [PDF]

, 2020
Jie Shi, Weiwei Zhang, Yixin Niu, Ning Lin, Xiaoyong Li, Hongmei Zhang, Renming Hu, Guang Ning, Jian‐Gao Fan, Li Qin, Qing Su, Zhen Yang   +11 more
openalex   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Measurement [PDF]

, 2020
openaire   +1 more source

Image_1_Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis.TIF

, 2021
Jiahui Liu (724342), Fangfang Fan (312738), Xingyu Luo (3684229), Wenjun Ji (822811), Yaokun Liu (11743949), Yan Zhang (8098), Bo Zheng (170888)   +6 more
openalex   +2 more sources

Mendelian randomization analysis of lipid-lowering drug targets and neuropsychiatric disorders. [PDF]

Medicine (Baltimore)
Peng S, Liu M, Du F, Li K.
europepmc   +1 more source